Alvotech 的 Simponi® 生物仿制药 AVT05 在治疗类风湿性关节炎方面表现出治疗等效性。 Alvotech's AVT05 biosimilar for Simponi® in rheumatoid arthritis shows therapeutic equivalence.

全球生物科技公司 Alvotech 宣布了其 AVT05 确认性临床研究的积极顶线结果，AVT05 是 Simponi®（戈利木单抗）的拟定生物仿制药，用于治疗中度至重度类风湿性关节炎患者。 Alvotech, a global biotech company, announced positive topline results from its confirmatory clinical study for AVT05, a proposed biosimilar for Simponi® (golimumab) in patients with moderate to severe rheumatoid arthritis. AVT05 被证实与 Simponi 具有治疗等效性，且未观察到显著的安全性差异。 AVT05 demonstrated therapeutic equivalence with Simponi and no significant safety differences were observed. Alvotech 计划今年在全球主要市场提交 AVT05 的营销申请。 Alvotech plans to file marketing applications for AVT05 in major global markets this year.